Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318484 | 0.98 | ALDH1A1 (0.35) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL28590124 | 0.77 | ALDH1A1 (0.33) | ALDH1A1KDM4ECRHR1POLBCYP2C9 | |
| SCHEMBL21843234 | 0.73 | HSP90AB1 (0.33) | ALDH1A1KDM4EGAACRHR1TSHR | |
| SCHEMBL5785398 | 0.67 | GAA (0.38) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL5789969 | 0.65 | MAPT (0.46) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL17844043 | 0.63 | RPS6KB1 (0.38) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL5826626 | 0.63 | AKT2 (0.52) | ALDH1A1KDM4E | |
| SCHEMBL317299 | 0.62 | RAPGEF4 (0.50) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL6972495 | 0.62 | KDM4E (0.52) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL2904246 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678793-B2 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1908764-A1 | Azolo triazines and pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-0915880-B1 | AZOLO TRIAZINES AND PYRIMIDINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252756-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY. | 2006-11-09 | — | — | US | disclosed |
| US-7094782-B1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1344779-A1 | Azolo-pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030008885-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-6358950-B1 | ADMINISTERING (1,5-A)-PYRAZOLO-1,3,5-TRIAZINE DERIVATIVES AS ANXIOLYTIC AGENTS AND ANTIDEPRESSANTS; CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; CARDIOVASCULAR, AUTOIMMUNE, NERVOUS SYSTEM, EATING, AND PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313124-B1 | AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS USED FOR THERAPY OF ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC, NEUROLOGICAL DISORDERS AS WELL AS TREATMENT OF IMMUNOLOGICAL, CARDIOVASCULAR OR HEART-RELATED DISEASES | DUPONT PHARMACEUTICALS COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-6191131-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-20 | — | — | US | disclosed |
| US-6136809-A | (1,5-A)-PYRAZOLO-PYRIMIDINES AND (1,5-A)-1,2,3-TRIAZOLO-PYRIMIDINES FOR TREATMENT OF CARDIOVASVULAR DISORDERS, STRESS AND PSYCHOLOGICAL DISORDERS WITH CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST | DUPONT PHARMACEUTICALS (US) | 2000-10-24 | — | — | US | disclosed |
| US-6124289-A | TREATING ANXIETY OR DEPRESSION IN MAMMALS | DUPONT PHARMACEUTICALS CO. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6060478-A | ANTIDEPRESSANTS | DUPONT PHARMACEUTICALS (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0915880-A1 | AZOLO TRIAZINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998003510-A1 | AZOLO TRIAZINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252756-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | ALDH1A1 2046/4885KDM4E 4689/4885LMNA 4599/4885 |
| US-20030008885-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | ALDH1A1 1805/4885KDM4E 4720/4885LMNA 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.